AMA Journal of Ethics^®

More transparent pricing would allow patients and families to make better decisions, but there are limitations to how reliably it promotes efficiency and market discipline.

Negative health consequences from costly care are referred to as financial toxicity and should be included in informed consent discussions.

Some clinicians offering image-guided procedures have little training in palliative medicine, which is both a clinical and an ethical problem.

Beatrice L. Brown joins Ethics Talk to discuss her article, coauthored with Dr Aaron S Kesselheim: "How Should Clinicians and Organizations Assess Risks and Benefits of First-in-Human Implantation of Investigational Devices?"

Information different patients need or want about cybersecurity risk varies, so communicating clearly is always key.

Heightened caution, improved physician and patient communication, and equitable access are key priorities.

Dr Donna-Bea Tillman joins Ethics Talk to discuss her article: "What Should the Public Know About Implantable Material and Device Innovation in the US?"

Device innovation has potential to improve patient outcomes over time, yet prospective benefits must be considered in light of risks.

Improving candidate evaluation and informed consent is key to motivating authenticity, not just voluntariness.

Clinician-researchers deeply invested in data gathering are still obliged to respect a patient-subject’s right to stop being in research.